Amgen Inc. (AMGN) Stock

Amgen Inc. trades at a P/E ratio of 25.26, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 13.28 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.92 suggests the stock may be undervalued relative to its growth rate.

With a beta of 0.50, Amgen Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 24.01 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Amgen Inc. achieves a profit margin of 17.40%, meaning it retains $17.40 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 28.70% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 105.70% and ROA at 7.04%, the company generates strong returns on invested capital.

Amgen Inc.'s revenue grew by 9.40% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 18.70% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry averages for proper context.

Amgen Inc. offers a dividend yield of 3.44%, paying $9.13 per share annually. This above-average yield of 2-4% provides meaningful income while still allowing the company to reinvest for growth. It compares favorably to the S&P 500 average and offers competitive returns versus bonds in the current rate environment. To receive the next dividend, shares must be purchased before the ex-dividend date of 5/16/2025.

The dividend sustainability can be assessed through the payout ratio - Amgen Inc. pays $9.13 per share in dividends against earnings of $10.97 per share, resulting in a payout ratio of 83.23%. This high payout ratio of 60-90% leaves limited earnings for reinvestment. While currently sustainable, there's less buffer for dividend growth or protection during earnings downturns. The next dividend payment is scheduled for 6/6/2025.

Amgen Inc. has a market capitalization of $149.01B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 537.71M shares outstanding, the company's ownership is relatively concentrated. As a major player in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry, it competes with other firms in this sector.

Amgen Inc.'s book value per share is $11.54, while the current stock price is $296.28, resulting in a price-to-book (P/B) ratio of 25.67. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

32 analysts cover AMGN with 47% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $314.27 implies 6.1% upside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:5 Strong Buy, 10 Buy, 14 Hold, 2 Sell, 1 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.